Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
P/B ratio for Trevena, Inc. (TRVN)
P/B ratio as of 2023: -1.74
According to Trevena, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.74. At the end of 2022 the company had a P/B ratio of 8.27.
P/B ratio history for Trevena, Inc. from 2011 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -1.74 |
| 2022 | 8.27 |
| 2021 | 36.89 |
| 2020 | 77.72 |
| 2019 | 64.08 |
| 2018 | 19.04 |
| 2017 | 68.65 |
| 2016 | 98.02 |
| 2015 | 80.32 |
| 2014 | 37.16 |
| 2013 | 107.25 |
| 2012 | -57071.80 |
| 2011 | 109.55 |